You are here: Industry Insights > Actemra

News List

Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children drugs
June 29, 2021
Genentech announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients
US approves Roche drug for emergency use against severe COVID-19 expresspharma
June 28, 2021
The US Food and Drug Administration (FDA) said yesterday that it had issued an emergency use authorisation (EUA) for Actemra to treat adults and pediatric patients hospitalised with COVID-19.
New products to drive systemic sclerosis market to $1.8 bn by 2030: GlobalData expresspharma
June 21, 2021
GlobalData expects Ofev and Actemra/RoActemra to reach peak global sales of $508.8 million in 2025 and $163.2 million in 2024, respectively.
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra® worldpharmanews
May 08, 2021
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche's Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid ...
Roche’s arthritis drug shows effectiveness for ill patients in Covid-19 trial pharmaceutical-technology
November 23, 2020
The UK’s Imperial College London has reported that early data from the REMAP-CAP trial showed Roche’s arthritis drug, Actemra (tocilizumab), is expected to reduce deaths and time spent in intensive care in critically ill patients with severe Covid-19.
Roche’s Phase III Trial of Actemra in COVID-19 Misses Primary Endpoint contractpharma
July 31, 2020
COVACTA trial did not meet primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoints.
Actemra/RoActemra, arthritis drug from Roche fails to meet primary endpoint of COVID-19 trial expresspharma
July 30, 2020
The COVACTA study did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia or identify any new safety signals for Actemra/RoActemra.
Roche to begin Covid-19 pneumonia trial with Actemra/RoActemra plus remdesivir pharmaceutical-business-review
June 02, 2020
Roche has announced the commencement of phase III clinical study of Actemra/RoActemra plus remdesivir in hospitalised patients with severe Covid-19 pneumonia.
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patien worldpharmanews
June 01, 2020
Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir ...
Roche Accelerates Phase III Actemra Trial in COVID-19 contractpharma
April 09, 2020
Receives $25 million in support from BARDA to evaluate safety and efficacy in severe COVID-19 pneumonia.

Previous page 1 2 Next page